Literature DB >> 11861092

Which continuous US scanning mode is optimal for the detection of vascularity in liver lesions when enhanced with a second generation contrast agent?

Raffaella Basilico1, Martin J K Blomley, Christopher J Harvey, Antonella Filippone, Rolf A Heckemann, Robert J Eckersley, David O Cosgrove.   

Abstract

OBJECTIVES: Microbubble echo-enhancers help in the assessment of focal liver masses by enhancing the signal from blood vessels. A variety of linear and nonlinear scanning modes are now available, but it is unclear which is optimal. A controlled comparison was performed during the infusion of such an agent (SonoVue: Bracco, Milan, Italy). METHODS AND MATERIALS: Ten patients with known focal liver lesions were studied. The diagnoses, confirmed on dual phase helical computed tomography (CT) at the same attendance were metastasis (n = 7), haemangioma (n = 2) and focal nodular hyperplasia FNH (n = 1). A dose of 12 ml SonoVue concentrated at 5 mg/ml was infused intravenously at a rate of 1 ml/min. The enhancement level was monitored with a continuous wave (CW) Doppler probe over the right radial artery and the intensity of the signal was registered at 1 s intervals. When a plateau of enhancement was reached, a single lesion in each patient was imaged using five different continuous scanning modes, fundamental grey scale (FGS); fundamental colour Doppler (FCD); fundamental power Doppler (FPD); second harmonic grey scale (HGS); and pulse inversion mode (Pim) using an HDI5000 scanner and C5-2 probe (ATL, Bothell, WA). The order of scanning modes was varied between patients using a predefined randomisation protocol. The videos (super video home system (SVHS)) were analysed offsite by two blinded readers, both experienced in contrast ultrasound of the liver. The readers were asked to score each mode in terms of its ability to detect vessels within/around the lesion at optimal enhancement. This was done using a ranking system (1, worst; 5, best) for each patient.
RESULTS: Both observers scored FPD as the optimal imaging method, followed by Pim. (Scores summed across all patients, observer 1: FPD 48, Pim 42, FCD 37, HGS 21, FGS 10; observer 2: FPD 49, Pim 40, FCD 38, HGS 21, FGS 10). The differences from FPD were significant for FCD, HGS and FGS using a unpaired analysis of variance (ANOVA) comparison, with Bonferroni multiple corrections, (P<0.01, both observers). The differences between FPD and Pim were also significant both for observer 2 and for both observers combined (P<0.01), but did not reach significance for observer 1 (P = 0.19).
CONCLUSIONS: In this study, FPD performed best, and the non-linear modes, performed continuously (pulse inversion and second HGS), showed no clear advantage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861092     DOI: 10.1016/s0720-048x(01)00459-4

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  11 in total

1.  Contrast-enhanced ultrasound: beyond the liver.

Authors:  L Thorelius
Journal:  Eur Radiol       Date:  2003-11       Impact factor: 5.315

Review 2.  [Ultrasound contrast agents for liver diagnostics].

Authors:  A-J Lemke; S S Chopra; S M Niehues; R Felix
Journal:  Radiologe       Date:  2005-06       Impact factor: 0.635

3.  [A new method for standardized diagnosis following renal transplantation. Ultrasound with contrast enhancement].

Authors:  T Fischer; V Ebeling; M Giessing; M Mühler; S Filimonow; J Dieckhöfer; A Lembcke; J Rudolph; S Morgera; K Budde; B Hamm; A Thomas
Journal:  Urologe A       Date:  2006-01       Impact factor: 0.639

4.  Diagnosis value of focal liver lesions with SonoVue®-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis.

Authors:  Yang Guang; LiMei Xie; Hailong Ding; AiLu Cai; Ying Huang
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-18       Impact factor: 4.553

5.  Contrast-enhanced ultrasonography to detect liver metastases : a prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy.

Authors:  R Konopke; S Kersting; H Bergert; A Bloomenthal; J Gastmeier; H D Saeger; A Bunk
Journal:  Int J Colorectal Dis       Date:  2006-05-30       Impact factor: 2.571

6.  Grey scale enhancement of rabbit liver and kidney by intravenous injection of a new lipid-coated ultrasound contrast agent.

Authors:  Ping Liu; Yun-Hua Gao; Kai-Bin Tan; Zheng Liu; Song Zuo
Journal:  World J Gastroenterol       Date:  2004-08-15       Impact factor: 5.742

7.  Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?

Authors:  R Vilana; L Bianchi; M Varela; C Nicolau; M Sánchez; C Ayuso; M García; M Sala; J M Llovet; J Bruix; C Bru
Journal:  Eur Radiol       Date:  2006-05-18       Impact factor: 7.034

8.  Second-generation sonographic contrast agents in the evaluation of renal trauma.

Authors:  G Regine; M Atzori; V Miele; V Buffa; M Galluzzo; M Luzietti; L Adami
Journal:  Radiol Med       Date:  2007-06-11       Impact factor: 3.469

Review 9.  When is contrast-enhanced sonography preferable over conventional ultrasound combined with Doppler imaging in renal transplantation?

Authors:  Markus Zeisbrich; Lars P Kihm; Felix Drüschler; Martin Zeier; Vedat Schwenger
Journal:  Clin Kidney J       Date:  2015-08-08

10.  Mucinous cystadenocarcinoma of the appendix in which contrast-enhanced ultrasonography was useful for assessing blood flow in a focal nodular lesion in the tumor cavity: A case report.

Authors:  Noritaka Wakui; Mitsuru Fujita; Yoshiya Yamauchi; Yuki Takeda; Nobuo Ueki; Takafumi Otsuka; Nobuyuki Oba; Shuta Nishinakagawa; Toshiko Takezoe; Junko Hiroyoshi; Yoshiharu Kono; Seiichiro Katahira; Masami Minagawa; Yasushi Takeda; Saori Shiono; Tatsuya Kojima
Journal:  Exp Ther Med       Date:  2013-04-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.